The primary objective of this study is to provide expanded access to and characterize the safety profile of Sotorasib in participants with previously treated locally advanced/unresectable/metastatic non small-cell lung cancer (NSCLC) with KRAS p.G12C mutation in a real-world setting.

Inclusion Criteria

• Age ≥ 18 years
• Ineligibility for participation in any Amgen-sponsored ongoing clinical study of the investigational product
• Pathologically documented, locally-advanced and unresectable or metastatic Non Small-Cell Lung Cancer (NSCLC) with KRAS p.G12C mutation confirmed through molecular testing
• Exhausted other standard of care options for locally advanced and unresectable or metastatic NSCLC disease including platinum-based combination chemotherapy and programmed cell death protein 1/programmed death-ligand 1 (PD 1/PD-L1) immunotherapy (unless medically contraindicated)
• Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2

Exclusion Criteria

• Mixed small-cell lung cancer or mixed NSCLC histology
• Active brain metastases
• Active hepatitis B or hepatitis C virus
• Current active malignancy other than NSCLC
• Currently or previously enrolled in a prior sotorasib study unless radiographic disease progression confirmed, able to remain on long term follow up of their original protocol and receives medical monitor approval
• Female participants planning to become pregnant while on study through 7 days after the last dose of sotorasib